Hunan Fangsheng Pharmaceutical Co., Ltd. Class A

Hunan Fangsheng Pharmaceutical Co., Ltd. Class A

SSSE:603998
10.54
CNY
+0.38
(+3.74%)
0.74EPS
13.94P/E
4.55BMarket Cap
Apr 23Next Earn
Hunan Fangsheng Pharmaceutical Co., Ltd. Class A
SSE:603998
(Shanghai Stock Exchange)

Recent

price

10.54

P/E

ratio

13.94

div

yld

4.92%

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.82
1.04
1.26
1.64
1.09
1.23
1.69
2.45
2.63
3.01
3.58
4.14
3.75
4.11
3.99
4.27
Revenue per Share
0.16
0.21
0.23
0.32
0.21
0.16
0.14
0.17
0.19
0.15
0.16
0.66
0.43
0.59
0.7
0.74
Basic EPS, GAAP
0.05
-0.07
0.21
-0.01
0.05
-0.11
-0.27
0.24
-0.09
0.16
- -
0.3
-0.3
0.23
0.64
- -
Free Cash Flow per Basic Share
0.02
0.02
0.02
- -
0.03
0.07
0.02
0.02
0.06
0.16
0.11
0.29
0.4
0.3
0.44
0.52
Dividend per Share
0.74
0.92
1.12
1.9
2.08
2.14
2.28
2.46
2.59
2.68
2.79
3.16
3.32
3.7
3.9
4.05
Book Value per Share
0.54
0.74
0.85
1.7
1.82
1.62
1.7
1.83
1.46
1.57
1.32
1.98
2.08
2.44
2.72
2.85
Tangible Book Value per Share
321
318
318
253
432
436
426
429
415
425
438
433
434
433
438
440
Basic Weighted Avg Shares
263
332
400
416
469
534
721
1,051
1,094
1,279
1,567
1,792
1,629
1,777
1,746
1,877
Sales/Revenue/Turnover
22.35
22.63
21.4
22.75
20.61
14.98
12.83
10.28
9.28
9.56
9.16
11.74
12.55
16
18.65
21.52
Operating Margin (%)
8
9
14
15
20
27
37
44
54
70
78
78
74
76
81
- -
Depreciation Expense
52
66
73
81
91
70
60
73
79
64
70
286
187
255
306
327
Net Income, GAAP
16.94
14.46
14.87
14.85
15.52
17.14
19.59
13.43
16.41
22.03
22.99
15.27
11.66
12.64
14.33
17.09
Effective Tax Rate (%)
19.75
19.9
18.35
19.49
19.35
13.06
8.28
6.94
7.21
4.99
4.47
15.95
11.47
14.36
17.54
17.41
Profit Margin (%)
120
142
180
567
604
316
231
230
-44
-93
-389
192
-327
-161
-137
-60
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
30
73
65
299
174
166
23
17
LT Debt
258
319
387
842
932
980
1,038
1,113
1,202
1,266
1,304
1,508
1,589
1,735
1,803
1,871
Total Equity
- -
22.19
20.34
13.07
10.3
6.99
5.97
6.63
5.75
3.43
4.23
14.36
7.99
10.59
13.07
14.98
Return on Invested Capital (%)
- -
22.6
20.06
12.13
9.01
6.72
5.44
5.92
6.27
5.32
4.69
16.23
9.87
11.89
13.83
15.39
Return on Capital (%)
- -
25
22.56
13.9
10.71
7.69
6.24
7.16
7.24
5.6
5.97
22.11
13.12
16.57
18.38
19.12
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
384
307
199
LT Borrowings
- -
- -
- -
LT Finance Leases
21
19
17
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
439
439
439
Market Capitalization
4,746
3,965
4,549

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,013
1,072
1,039
Cash, Cash Equivalents & STI
254
308
248
Accounts Receivable, Net
250
270
297
Inventories
351
357
354
Total Current Liabilities
1,120
1,130
1,098
Payables & Accruals
- -
- -
- -
ST Debt
384
307
199
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.88%
7.43%
3.92%
Free Cash Flow
1,302.71%
2,768.84%
181.67%
Net Income, GAAP
31.37%
67.99%
20.05%
Sales/Revenue/Turnover
15.09%
7.04%
-1.75%
Total Cash Common Dividend
58.95%
39.39%
49.24%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
438
472
438
430
1,777
2025
418
416
- -
493
1,746
2026
463
495
426
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.15
0.21
0.06
0.59
2025
0.2
0.18
- -
0.09
0.7
2026
0.2
0.25
0.21
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.23
0.01
0.04
0.3
2025
0.07
0.21
- -
0.01
0.44
2026
0.15
0.15
0.2
- -
- -
Business
Hunan Fangsheng Pharmaceutical Co., Ltd. Hunan Fangsheng Pharmaceutical Co., Ltd. (603998.SS) is a China-based pharmaceutical company principally engaged in the research, development, production, and sales of innovative traditional Chinese medicines and chemical drugs. The company manufactures and markets a wide range of products including garcinia cambogia tablets (藤黄健骨片), Xuesetong dispersible tablets and tablets for cardiovascular and cerebrovascular conditions, powerful loquat cream lotion, Ezhemab tablets, Xuanqi bone tablets for orthopedics, children's Jingxing cough tablets and small children's Jingxing cough granules for pediatric respiratory issues, Hesketone dispersible tablets, lysine vitamin B12 granules, cefixime tablets for anti-infection, Jinying capsules for gynecology, Pudilan anti-inflammatory tablets, Dieda Huoxue capsules for traumatology, and Xiaoqinglong capsules; these are offered in forms such as tablets, capsules, granules, oral suspensions, powders, suppositories, powder-injections, and tinctures targeting orthopedic, cardiovascular and cerebrovascular, anti-infection, pediatric, gynecological, respiratory, and other diseases. Founded in 2002 and headquartered in Changsha, Hunan province, the company operates six major production bases across China, focuses on the pharmaceutical manufacturing segment with emphasis on proprietary Chinese medicines, and integrates big health industries and medical services as a high-tech enterprise listed on the Shanghai Stock Exchange since December 5, 2014. Recent developments include its subsidiary Guangdong Fangsheng Rongke Pharmaceutical receiving clinical trial approval for a prostate cancer drug and Ziying for innovative traditional Chinese medicine in 2025, Phase 2 trial success for a stroke treatment showing superior efficacy, acquisition of licensing rights for Xiaoqinglong capsules in February 2025, extension for a blood cholesterol drug production facility, receipt of a drug registration certificate for Indobufen tablets, recognition as a 2025 National Green Factory and ranking in the top 20 Chinese traditional Chinese medicine R&D strengths in June 2025, changes in partnership shares of its merger and acquisition fund in December 2024 without impacting consolidated statements, and cancellation of a 26.65% stake acquisition in Hunan Baijun Hi-Tech Medical Investment Management Co., Ltd. in early 2025.